Servier and Aitia Mobilize AI and Digital Twins to Treat Pancreatic Cancer

The French pharmaceutical group Servier and Aitia announced on May 17th a multi-year partnership agreement for the discovery and simulation of drugs in pancreatic cancer. It is based on the combination of Servier’s expertise in preclinical trials with Aitia’s technology, which is based on artificial intelligence and Gemini Digital Twins. Read more on the latest […]

Colin Hill Weighs in on the Future of Drug Discovery on the Patients Rising Podcast

Our CEO, Colin Hill was a special guest on the Patients Rising Podcast. In this week’s episode, Colin passionately shared his beliefs and vision for the future of medical research, highlighting the transformative potential of AI-powered clinical trials and the revolutionary power of Digital Twins. Tune in to the podcast episode now and discover how Digital […]

Open to Debate: Is the FDA’s Caution Hazardous to your Health?

During the COVID-19 pandemic, the Atlantic lambasted the US Food and Drug Administration for moving too slowly to approve vaccines with the provocative headline “The Death Toll of Delay.” Not long before, National Public Radio had run a piece titled “One-Third of New Drugs Had Safety Problems After FDA Approval.” As the agency tries to […]

World Congress: AI and Digital Twins to Drive the Next Generation Drug Discovery and Development

Watch Colin Hill’s talk at Charles River’s sixth Annual World Congress on May 11, 2023, in Cambridge, MA. Colin’s session focused on “Al and Digital Twins to Drive the Next Generation of Drug Discovery and Development”. The presentation was followed by a fireside chat with Julie Frearson, Chief Scientific Officer at Charles River Laboratories. This […]

Servier Doubles Up on Digital Twin Alliance with Aitia

The new project will focus on pancreatic cancer, and builds on a collaboration in the blood cancer multiple myeloma that was started by the two companies last year. Read more on the latest collaboration between Servier and Aitia, in Pharmaphorum article. Full article here. Picture Credit: Pharmaphorum

Companies to Focus on Therapeutic Targets Showing Cause and Effect

Aitia has been featured in Huntington’s Disease News for its collaboration with UCB to develop a new treatment for Huntington’s disease. The article highlights Aitia’s expertise in Causal AI as “a new branch of artificial intelligence that goes beyond establishing links between variables: It makes decisions and predictions based on cause and effect.” The collaboration […]

UCB Enters Drug Discovery Collaboration with Aitia

Aitia latest strategic drug discovery collaboration with UCB, focused on the discovery and validation of novel drug targets and drug candidates for Huntington’s disease. The collaboration will combine the use of new drug targets for Huntington’s disease from Aitia’s Gemini Digital Twins with the expertise of UCB in preclinical model systems and drug research in neurodegeneration for advancing […]

Research Identifies Potential New Biomarkers of Atherosclerotic Coronary Artery Disease

“This landmark result clearly demonstrates the power of causal AI and Digital Twins to reveal the hidden circuitry of cardiovascular disease from large-scale multi-omic data”, said Colin Hill, CEO and co-founder of Aitia. “Seventy years of cardiovascular biology including LDL, PCSK9, and Lp(a) were reconstructed in a hypothesis-free fashion in a few months, which created the […]

Becoming Aitia: Why GNS Shifted from AI Provider to Drug Discoverer

January 2023, GNS announced a rebrand as Aitia to focus on AI-enabled drug drug discovery. CEO Colin Hill told BioCentury the company considered the shift five years ago, seeing appetite from investors and pharma partners. “Aitia’s decision to move into drug discovery after more than 20 years as a technology partner is a bet on […]

New Biomarkers for Atherosclerosis Found Using Digital Twins

Newly identified markers of atherosclerotic coronary artery disease (ASCAD) were pinpointed in a study using digital twins. The work was carried out by multi-omics specialist G3 Therapeutics and AI company Aitia, which has Gemini Digital Twin technology. These new findings suggest triglyceride-rich LDL particles could be a novel diagnostic marker for ASCAD and could also […]